The role of RBM10 mutations in the development, treatment, and prognosis of lung adenocarcinoma. Issue 21 (1st November 2020)

• Record Type: Journal Article
• Authors: Li, Zhenqing; Xue, Qun; Xu, Jianxun; Zhang, Pengfei; Ding, Bo
• Is Part Of: Cell cycle. Volume 19:Issue 21(2020)
• Page Start: 2918
• Page End: 2926
• Publication Date: 2020-11-01
• Subjects: Lung adenocarcinoma -- RBM10 mutation -- TCGA -- RNA-seq -- bioinformatics analysis; Cell cycle -- Periodicals; 571.84377
• DOI: 10.1080/15384101.2020.1829801
• Languages: English
• ISSNs: 1538-4101

Abstract

ABSTRACT: RBM10 is the RNA-binding protein often absent or mutated in lung adenocarcinoma, rendering it as a potential biomarker or even therapeutic target to prolongate survival time. In this study, we investigated the involvement of RBM10 mutation in the pathogenesis and tumorigenesis of lung adenocarcinoma and identified the differentials in relative signal pathways, aiming to provide the new therapeutic approaches. By performing the systematic TCGA analysis, our results demonstrated that RBM10 mutation was identified in 6% lung adenocarcinoma patients, meanwhile 113 functional genes were identified as significant expression among these patients. Further gene ontology and KEGG analysis were employed to identify the most relative 10 genes and signal pathways. Moreover, four members of the 5-acyl-6, 7-dihydrothiophene [3, 2-c] pyridine (known as "ru-ski")-ru-ski 43 were identified as the potential drugs for RBM10 mutation lung adenocarcinoma therapy, investigated by the GDSC database. Meanwhile there were 157 genes that were more frequently mutated in the RBM10 mutation group than the wild-type group ( p value<0.05). KEGG analysis showed that these genes were enriched in various cancer development pathways and cell proliferation. Finally, our investigations provided the glance at the differential genes and cellular signaling pathways related to RBM10 mutation and identified series of potential drugs for personalized RBM10 mutation lung adenocarcinoma therapy.